Cleerly named to Fierce Medtech's 2021 Fierce 15

In one way or another, the Fierce 15 has always been about celebrating those who are finding new ways of doing things, whether it’s innovators creating novel treatments for patients in need or developers wielding the latest technologies to reinvent standard healthcare practices.

By Conor Hale, Andrea Park, Heather Landi, Rebecca Torrence, Kyle LaHucik, and Max Bayer

But after the first two years of the COVID-19 pandemic forced every player in the medtech industry to try their hands at something new—be it working remotely, dealing with supply chain snafus or even pivoting their entire business model to take on the coronavirus, like some members of 2020's Fierce 15—how do you decide where to shine the spotlight?

This year’s class of 15 companies—our 10th annual selection—stand out from the pack because they are working to build new ways to approach the day to day: through providing remote diagnostics, in-home healthcare or ways for researchers to work and collaborate virtually. Their offerings include lifesaving devices you can hold in your hand as well as massive, intangible networks of data sculpted to help answer the future’s pressing questions, from the personal to the professional. Read the full article here.

About Cleerly

Cleerly is the company creating a new standard of care for heart disease. Through value-based precision diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: https://www.cleerlyhealth.com.

Cleerly Press Contact:

press@cleerlyhealth.com